9.68
Schlusskurs vom Vortag:
$9.29
Offen:
$9.27
24-Stunden-Volumen:
614.33K
Relative Volume:
0.55
Marktkapitalisierung:
$780.89M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-209.96M
KGV:
-3.0633
EPS:
-3.16
Netto-Cashflow:
$-176.27M
1W Leistung:
-1.23%
1M Leistung:
+7.24%
6M Leistung:
-20.48%
1J Leistung:
+2.88%
Replimune Group Inc Stock (REPL) Company Profile
Firmenname
Replimune Group Inc
Sektor
Branche
Telefon
(781) 222-9600
Adresse
500 UNICORN PARK, WOBURN, MA
Vergleichen Sie REPL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
REPL
Replimune Group Inc
|
9.69 | 780.89M | 0 | -209.96M | -176.27M | -3.16 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
456.75 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
547.09 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
324.57 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
555.67 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
246.00 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Replimune Group Inc Stock (REPL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2024-08-28 | Eingeleitet | ROTH MKM | Buy |
2023-04-17 | Fortgesetzt | Piper Sandler | Overweight |
2021-11-19 | Eingeleitet | Piper Sandler | Overweight |
2021-10-15 | Fortgesetzt | BTIG Research | Buy |
2020-11-17 | Eingeleitet | BTIG Research | Buy |
2020-11-02 | Eingeleitet | Jefferies | Buy |
2020-10-15 | Hochstufung | H.C. Wainwright | Neutral → Buy |
2020-07-01 | Herabstufung | H.C. Wainwright | Buy → Neutral |
2020-05-05 | Eingeleitet | Barclays | Overweight |
2019-09-04 | Eingeleitet | ROTH Capital | Buy |
2019-07-23 | Eingeleitet | Chardan Capital Markets | Buy |
2019-07-12 | Hochstufung | JP Morgan | Neutral → Overweight |
2019-07-08 | Eingeleitet | H.C. Wainwright | Buy |
2019-04-25 | Eingeleitet | Wedbush | Outperform |
2019-01-23 | Herabstufung | JP Morgan | Overweight → Neutral |
2018-08-14 | Eingeleitet | JP Morgan | Overweight |
2018-08-14 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Replimune Group Inc Aktie (REPL) Neueste Nachrichten
GAMMA Investing LLC Boosts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Shares Sold by Bank of America Corp DE - Defense World
California State Teachers Retirement System Boosts Holdings in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 15,402 Shares of Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Squarepoint Ops LLC Cuts Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Replimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REPL Stock News - GuruFocus
Replimune Group, Inc. Grants Inducement Equity Awards to New Employees Under 2025 Plan - Nasdaq
Replimune Group, Inc. (REPL) Stock Analysis: A Biotech Gem with 124% Potential Upside - DirectorsTalk Interviews
JPMorgan reiterates overweight rating on Replimune stock after ASCO By Investing.com - Investing.com Canada
Replimune Group (NASDAQ:REPL) Price Target Raised to $22.00 at Piper Sandler - Defense World
Piper Sandler raises Replimune stock price target after updates By Investing.com - Investing.com South Africa
Piper Sandler raises Replimune stock price target after updates - Investing.com Australia
Does Replimune Group Inc (NASDAQ: REPL) Still Need To Convince Analysts? - Stocksregister
Replimune Group (REPL) Price Target Raised by Piper Sandler Anal - GuruFocus
Replimune Group (REPL) Price Target Raised by Piper Sandler Analyst | REPL Stock News - GuruFocus
Replimune (REPL) Price Target Raised by Piper Sandler Amid Positive Developments | REPL Stock News - GuruFocus
BNP Paribas Financial Markets Trims Stake in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune (REPL) Highlights Promising RP1 Data at ASCO 2025 | REPL Stock News - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plu - GuruFocus
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting | REPL Stock News - GuruFocus
Replimune Reports Promising Clinical Data for RP1 Plus Nivolumab at ASCO 2025, Highlighting Robust Responses and Safety Profile - Nasdaq
Replimune Presents New Analyses From The IGNYTE Study Of RP1 Plus Nivolumab In Anti-PD1 Failed Melanoma At The 2025 American Society Of Clinical Oncology (ASCO) Annual Meeting - marketscreener.com
Replimune Presents New Analyses from the IGNYTE Study of RP1 plus Nivolumab in Anti-PD1 Failed ... - Enidnews.com
Replimune's RP1 Achieves 33% Response Rate in Anti-PD1 Failed Melanoma Trial | REPL Stock News - Stock Titan
ProShare Advisors LLC Grows Stock Position in Replimune Group, Inc. (NASDAQ:REPL) - Defense World
Replimune Group (NASDAQ:REPL) Trading Down 5.9% – Time to Sell? - Defense World
Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Buy” from Analysts - Defense World
Replimune to Present at the 2025 Jefferies Global Healthcare Conference - The Manila Times
Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Nuveen Asset Management LLC - Defense World
Why Okta Stock Plunged on Wednesday - The Globe and Mail
HC Wainwright Estimates Replimune Group Q3 Earnings - Defense World
Leerink Partnrs Estimates Replimune Group Q1 Earnings - Defense World
Replimune’s SWOT analysis: biotech firm’s stock poised for growth amid FDA review - Investing.com India
Replimune director sells $260,168 in common stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. (NASDAQ:REPL) Q4 2025 Earnings Call Transcript - Insider Monkey
Replimune (REPL) Plans Major Stock Sale with 25.1M Shares Offeri - GuruFocus
Replimune Group Inc Files For Offer & Resale Of 25.1 Million Shares Of Common Stock Offered By Selling StockholdersSEC Filing - marketscreener.com
Replimune Group Inc Files For Mixed Shelf Of Up To $250 MillionSEC Filing - marketscreener.com
Replimune (REPL) Announces $250 Million Securities Shelf Filing | REPL Stock News - GuruFocus
Replimune Group, Inc. (REPL) Stock Analysis: An Insight into a Biotech Gem with 141% Upside Potential - DirectorsTalk Interviews
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial ... - Yahoo Finance
Stock Traders Buy High Volume of Call Options on Replimune Group (NASDAQ:REPL) - Defense World
Replimune Group Inc (REPL) Q4 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Replimune director sells $260,168 in common stock - Investing.com Australia
Replimune Group Advances Oncolytic Immunotherapy Pipeline - TipRanks
Replimune’s chief commercial officer sells $30,179 in stock By Investing.com - Investing.com South Africa
Replimune Group, Inc. SEC 10-K Report - TradingView
REPLIMUNE GROUP Earnings Results: $REPL Reports Quarterly Earnings - Nasdaq
Finanzdaten der Replimune Group Inc-Aktie (REPL)
Umsatz
Nettogewinn
Free Cashflow
ENV
Replimune Group Inc-Aktie (REPL) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
Xynos Konstantinos | Chief Medical Officer |
May 20 '25 |
Sale |
8.06 |
7,952 |
64,093 |
146,933 |
Schwendenman Andrew | Chief Accounting Officer |
May 20 '25 |
Sale |
8.05 |
3,287 |
26,460 |
68,284 |
Patel Sushil | Chief Executive Officer |
May 20 '25 |
Sale |
8.06 |
25,105 |
202,346 |
343,576 |
Hill Emily Luisa | Chief Financial Officer |
May 20 '25 |
Sale |
8.05 |
2,535 |
20,407 |
143,522 |
Sarchi Christopher | Chief Commercial Officer |
May 20 '25 |
Sale |
8.05 |
3,749 |
30,179 |
128,296 |
Patel Sushil | Chief Executive Officer |
Dec 16 '24 |
Sale |
12.42 |
10,000 |
124,200 |
202,014 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):